多形膠芽腫治療市場規模、シェア、成長分析、治療タイプ別、エンドユーザー別、地域別 - 産業別予測、2024～2031年

多形膠芽腫治療の世界市場規模は、2022年に24億6,000万米ドルと評価され、2023年の27億米ドルから2031年には56億6,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは9.7%で成長する見通しです。

多形膠芽腫治療市場は、膠芽腫症例の急増と研究開発への注力の高まりにより、大幅な成長が見込まれています。2020年の脳腫瘍による死亡者数は25万1,000人以上、診断者数は30万8,000人以上というGlobal Cancer Observatoryの憂慮すべき統計を受けて、大手製薬企業は製品パイプラインを強化しています。WHOが2021年に発表したエビデンスによると、脳腫瘍の発生件数は24万5,000件以上であり、効果的な治療オプションの必要性が高まっています。しかし、市場は高い治療費やこの攻撃的ながんに対する効果的な治療法の開発という課題を含むハードルに直面しています。とはいえ、個別化医療の進歩や有望な臨床試験の結果に後押しされ、免疫療法、標的治療、革新的な併用療法にチャンスがあふれています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーター分析と影響
  • 競争企業間の敵対関係
  • 代替品の脅威
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 供給企業の交渉力

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 特許分析
• ケーススタディ

多形膠芽腫治療市場規模：治療タイプ別

• 市場概要
• 化学療法
  • テモゾロミド
  • ベバシズマブ
  • カルムスチン
  • ロムスチン
  • その他
• 放射線治療
  • 外部放射線治療（EBRT）
  • 近接放射線療法
• 標的療法
  • モノクローナル抗体
  • チロシンキナーゼ阻害剤
• 免疫療法
  • チェックポイント阻害剤
  • ワクチン療法
• 腫瘍治療電場（TTF）療法
• 手術
  • 頭蓋切開術
  • 生検

多形膠芽腫治療市場規模：エンドユーザー別

• 市場概要
• 病院
• クリニック
• 外来手術センター
• 調査機関

多形膠芽腫治療市場規模：地域別

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021-2023）

主要企業プロファイル

• Roche Holding AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Sanofi S.A.
• Bayer AG
• AstraZeneca plc
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ipsen S.A.
• Sumitomo Dainippon Pharma Co., Ltd.
• Karyopharm Therapeutics Inc.

結論と推奨事項

Global Glioblastoma Multiforme Treatment Market size was valued at USD 2.46 billion in 2022 and is poised to grow from USD 2.70 billion in 2023 to USD 5.66 billion by 2031, growing at a CAGR of 9.7% during the forecast period (2024-2031).

The glioblastoma multiforme treatment market is poised for substantial growth, driven by a surge in glioblastoma cases and a heightened focus on research and development. Major pharmaceutical companies are bolstering their product pipelines, responding to the alarming statistics from the Global Cancer Observatory, which noted over 251,000 deaths and 308,000 diagnoses of brain cancers in 2020. Added evidence from the WHO in 2021 highlighted more than 245,000 occurrences of such tumors, amplifying the need for effective treatment options. However, the market faces hurdles, including high treatment costs and the challenge of developing effective therapies for this aggressive cancer. Nevertheless, opportunities abound in immunotherapy, targeted treatments, and innovative combinations, fueled by advancements in personalized medicine and promising clinical trial outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glioblastoma Multiforme Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glioblastoma Multiforme Treatment Market Segmental Analysis

Global Glioblastoma Multiforme Treatment Market is segmented by treatment type, end user and region. Based on treatment type, the market is segmented into chemotherapy (temozolomide, bevacizumab, carmustine, lomustine, others), radiation therapy (external beam radiation therapy (EBRT), brachytherapy), targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors), immunotherapy (checkpoint inhibitors, vaccine therapy), tumor treating fields (TTF) therapy and surgery (craniotomy, biopsy). Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market is primarily driven by several key factors. The increasing prevalence of glioblastoma, a particularly aggressive form of brain cancer, continues to spur demand for effective treatment options. Advancements in medical technology and innovative therapeutic approaches, such as targeted therapies and immunotherapy, are enhancing treatment efficacy and patient outcomes. Additionally, rising investments in research and development, along with the growing focus on personalized medicine, are fostering the introduction of new drugs and therapies into the market. Moreover, heightened awareness of glioblastoma and improved access to healthcare services are contributing to market expansion globally.

Restraints in the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market faces several constraints that could hinder its growth. Key challenges include the high costs associated with treatment options, which may limit access for many patients. Additionally, the complex nature of glioblastoma, characterized by its aggressive behavior and resistance to conventional therapies, presents a significant barrier to effective treatment. Furthermore, a lack of robust clinical data and ongoing research may delay the introduction of new and innovative therapies. Regulatory hurdles and the need for extensive clinical trials can also impede market expansion, while the limited number of healthcare professionals specializing in this area adds to the market's challenges.

Market Trends of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme (GBM) Treatment market is witnessing a significant trend towards increased adoption of personalized medicine, revolutionizing standard treatment paradigms. This shift leverages advancements in genetic profiling and biomarker testing, enabling healthcare providers to tailor therapies to the unique characteristics of each patient's tumor. Such precision approaches not only enhance treatment efficacy but also minimize the risk of adverse effects, reflecting a broader movement towards individualized healthcare solutions. As stakeholders invest in research and technology to develop targeted therapies, the market is poised for growth, driven by rising awareness and the potential for improved patient outcomes in GBM management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Glioblastoma Multiforme Treatment Market Size by Treatment Type & CAGR (2024-2031)

• Market Overview
• Chemotherapy
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • Others
• Radiation Therapy
  • External Beam Radiation Therapy (EBRT)
  • Brachytherapy
• Targeted Therapy
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
• Immunotherapy
  • Checkpoint Inhibitors
  • Vaccine Therapy
• Tumor Treating Fields (TTF) Therapy
• Surgery
  • Craniotomy
  • Biopsy

Global Glioblastoma Multiforme Treatment Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes

Global Glioblastoma Multiforme Treatment Market Size & CAGR (2024-2031)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation